A new treatment for squamous cell lung cancer using targeted therapy
Official title: R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma
Funded at Boston University (Charles River Campus) · NIH-10671669 · Data updated 2026-11-12
This study is testing a new treatment for squamous cell lung cancer that uses a special drug designed to deliver chemotherapy directly to cancer cells, which could help patients feel better and live longer while protecting healthy tissues.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $226,784 |
| NIH project number | 5R21CA273645-02 |
| Project ID | NIH-10671669 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with squamous cell lung carcinoma who have limited treatment options.
✕Less likely to help
Patients with other types of lung cancer or those who do not have squamous cell carcinoma may not benefit from this research.
What this research studies
This research investigates a novel therapy for squamous cell lung carcinoma (SCC) that utilizes an antibody-drug conjugate (ADC) to deliver a potent chemotherapy drug directly to cancer cells. The approach targets tumors that overexpress a specific receptor, allowing for more effective treatment while minimizing damage to healthy tissues. By using a new method for drug conjugation, the therapy aims to enhance the stability and efficacy of the treatment. Patients with SCC may benefit from this targeted approach, which could lead to improved survival rates.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with squamous cell lung carcinoma, potentially improving survival rates.
How similar studies have gone: Previous research has shown promise with similar antibody-drug conjugate approaches in treating various cancers, suggesting potential for success in this novel application.
Where this research is happening
-
Boston University (Charles River Campus)
Boston, United States Active
Researchers
- Principal investigator: Grinstaff, Mark W. — Boston University (Charles River Campus)
- Study coordinator: Grinstaff, Mark W.
Related research
Other NIH-funded projects on the same topics.
-
Targeting immune vulnerabilities in small cell lung cancer
A physician-scientist is undergoing a five-year training program to understand how immune cells interact with small cell lung cancer and to build skills for a future independent lab career.
-
Investigating immune weaknesses in small cell lung cancer
This study is looking at how the immune system works with small cell lung cancer to find new ways to help it fight the disease, and it's designed for patients who want to learn more about potential treatments.
-
How small cell lung cancer cells switch between different states
This research looks at how cells inside small cell lung cancer change into different types and how those changes affect treatment for people with SCLC.
-
Understanding how small cell lung cancer adapts and resists treatment
This study is looking at small cell lung cancer to understand why it grows so quickly and resists treatment, using special models from patients to find new ways to improve care for people facing this tough disease.
-
Combining targeted therapies to treat difficult lung cancer cases
This study is testing a new way to treat advanced non-small cell lung cancer by using a special self-injectable medicine that targets specific proteins causing the cancer, with the hope of making treatments work better for patients.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.